<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858412</url>
  </required_header>
  <id_info>
    <org_study_id>20-1194</org_study_id>
    <nct_id>NCT04858412</nct_id>
  </id_info>
  <brief_title>Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19</brief_title>
  <official_title>Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are&#xD;
      at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory&#xD;
      failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with&#xD;
      anabolic properties, increases muscle mass and contractile function and enhances immune&#xD;
      function. We aim to study the natural course of COVID-19 in patients with ALD and test&#xD;
      whether HMB can affect ventilatory deterioration and improve short and long-term morbidity,&#xD;
      mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skeletal muscle mass at Day 0 and Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of hospital admissions between Day 0 and Day 90</measure>
    <time_frame>Baseline and Day 90</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <condition>COVID 19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>HMB enriched amino acid arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced amino acid arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>β-hydroxy β-methyl butyrate (HMB) enriched amino acid</intervention_name>
    <description>β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.</description>
    <arm_group_label>HMB enriched amino acid arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Balanced amino acid</intervention_name>
    <description>Balanced amino acid is the balanced mixture of the various essential amino acids.</description>
    <arm_group_label>Balanced amino acid arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. Cases: Patients with ALD and COVID-19 pneumonia:&#xD;
&#xD;
          1. Clinical, imaging, laboratory, and/or histological diagnosis of alcoholic cirrhosis&#xD;
             and/or alcoholic hepatitis&#xD;
&#xD;
          2. Child Pugh score 5-8, serum creatinine &lt;3, Model for End Stage Liver Disease score&#xD;
             (MELD) &lt;25&#xD;
&#xD;
          3. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2&#xD;
             infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph&#xD;
             (CXR) or computed tomography (CT) and SpO2 &lt;93% or on oxygen supplement&#xD;
&#xD;
          4. Age of 21 years or older&#xD;
&#xD;
        B. Controls: Patients without alcoholic liver disease (Non-ALD) and COVID-19 pneumonia:&#xD;
&#xD;
          1. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2&#xD;
             infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph&#xD;
             (CXR) or computed tomography (CT) and SpO2 &lt;93% or on oxygen supplement&#xD;
&#xD;
          2. Age of 21 years or older&#xD;
&#xD;
        Exclusion Criteria: (Both Cases and Controls)&#xD;
&#xD;
          1. Patients requiring active ventilator support&#xD;
&#xD;
          2. Anticoagulant/antiplatelet therapy (for those in the biopsy arm, see Randomization&#xD;
             schema. If clinically feasible, patients will be asked to hold their anticoagulants&#xD;
             for the muscle biopsy after physician review),&#xD;
&#xD;
          3. Recent gastrointestinal bleeding (&lt;3 months)&#xD;
&#xD;
          4. Advanced organ diseases: congestive heart failure (NYHA class 3 and 4), chronic&#xD;
             obstructive pulmonary diseases (COPD) (GOLD stage 3 and 4), chronic kidney disease&#xD;
             (Cr&gt;3), metastatic malignancy&#xD;
&#xD;
          5. Medications that alter muscle protein metabolism except systemic corticosteroids&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Unwillingness/ Inability to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivasan Dasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annette Bellar, MSLA</last_name>
    <phone>216-445-0688</phone>
    <email>bellara@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alina Tuladhar, MPH</last_name>
    <phone>216-445-6268</phone>
    <email>tuladha@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Bellar, MSLA</last_name>
      <phone>216-445-0688</phone>
      <email>bellara@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Alina Tuladhar, MPH</last_name>
      <phone>216-445-6268</phone>
      <email>tuladha@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Dasarathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

